Aurora-A/STK-15 is a predictive factor for recurrent behaviour in non-invasive bladder carcinoma: a study of 128 cases of non-invasive neoplasms

Compérat, Éva; Camparo, Philippe; Haus, R.; Chartier-Kastler, E.; Radenen, B.; Richard, François; Capron, Frédérique; Paradis, Valérie

doi:10.1007/s00428-007-0383-x

Cited by 40 publications

(24 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In practice, this could mean that papillary urothelial neoplasms of low malignant potential and noninvasive papillary low-grade cancer with an absence of Aurora-A expression would require less frequent follow-up. The same study also demonstrated that the combination of Aurora-A and Ki-67 had a powerful predictive value for recurrence in multivariate analysis ( table 1 ) [83] .…”

Section: Aurora-a/stk15mentioning

confidence: 68%

“…In addition, Aurora-A overexpression may serve as an independent factor in predicting recurrence of pTa/pT1 tumors ( table 2 ) [82] . Similarly, immunostaining of Aurora-A in pTa tumors was demonstrated to be a good predictive factor for recurrence, especially in papillary urothelial neoplasms of low malignant potential and noninvasive papillary lowgrade cancer, while it was less useful in noninvasive papillary high-grade cancer and cancer in situ [83] . In practice, this could mean that papillary urothelial neoplasms of low malignant potential and noninvasive papillary low-grade cancer with an absence of Aurora-A expression would require less frequent follow-up.…”

Section: Aurora-a/stk15mentioning

confidence: 99%

See 1 more Smart Citation

Current Status of Prognostic Immunohistochemical Markers for Urothelial Bladder Cancer

Rosenblatt¹,

Jonmarker²,

Lewensohn³

et al. 2008

Tumor Biol

View full text Add to dashboard Cite

The management and prognostication of patients with urothelial carcinomas (UCs), the most common histological type of bladder cancer, is mainly based on clinicopathological parameters. Several markers have been proposed to monitor this disease, including individual cell cycle-related proteins such as p53, pRb, p16, p21 and p27. Other putative markers are the oncogene products of FGFR3 and the ErbB family, proliferation markers including Ki-67, Aurora-A and survivin and different components within the immune system. In this review, a total of 12 parameters were evaluated and their discriminatory power compared. It is concluded that, in single-marker analyses, the proliferation markers Ki-67, survivin and Aurora-A offer the best potential to predict disease progression since they were all able to demonstrate independent prognostic power in repeated studies. Markers related to the immune system (e.g. CD8+ cells, regulatory T cells and cyclooxygenase-2 expression) or oncogene products of the ErbB family and FGFR3 are less powerful predictors of outcome or have not been equally well studied. The cell cycle-related proteins p53, pRb, p16, p21 and p27 have been extensively studied, but their usefulness as single prognostic markers remains unclear. However, in multimarker analyses, these markers appear to add prognostic information, indicating that they may contribute to more accurate treatment of UC.

show abstract

Section: Aurora-a/stk15mentioning

confidence: 68%

Section: Aurora-a/stk15mentioning

confidence: 99%

Current Status of Prognostic Immunohistochemical Markers for Urothelial Bladder Cancer

Rosenblatt¹,

Jonmarker²,

Lewensohn³

et al. 2008

Tumor Biol

View full text Add to dashboard Cite

show abstract

“…p53 and MIB-1 usually display strong nuclear staining in Cis. Aurora-A is overexpressed in the cytoplasm and perinuclear in Cis, it has also been shown that overexpression of these 3 markers predicts relapse (30). One should also think of Cis extending to von Brunn Nests, or exclusively being present in the latter.…”

Section: Urothelial Carcinoma In Situ (Cis)/involvement Of Von Brunsmentioning

confidence: 99%

Fluorescence diagnosis and flat lesions of urothelium: New challenges for pathologists and urologists (Review)

Compérat¹

2009

Oncol Rep

View full text Add to dashboard Cite

Abstract. Bladder cancer is a common malignancy. Recurrence rate and progression vary greatly depending on factors such as tumor multiplicity, size, previous recurrence rates, tumor stage, tumor grade and the presence of carcinoma in situ. Treatment is expensive, recent studies demonstrated that superficial bladder cancer is a major economic burden. It is necessary to establish new kinds of techniques to improve diagnosis, therapy and follow-up, such as fluorescence diagnosis, without adding significant risk of complications. As urologists have a better sight of bladder lesions with fluorescence diagnosis, pathologists will be asked in the future to evaluate more frequently flat lesions, which up to now would not have been a matter of concern. For several reasons it is very important to have accurate and precise definitions of these flat lesions. First to permit uniform treatment of large groups of patients and second to see in large cohorts the evolution and natural history of several flat lesions, not always well known up to now. The aim of the study was to review the most important flat lesions, to demonstrate the difficulty of classifying several lesions, to introduce to urologists the new problems linked to FD and to suggest new models for accurate analysis. How far can we go in our answer as pathologists and how will it change the patient management?

show abstract

“…It is a known predictive factor of recurrence in UC and its overexpression has been shown to be a prognostic factor for bad clinical outcome [3] .…”

Section: Introductionmentioning

confidence: 99%

“…Evaluation of p53 gene and protein status provides information in assessing the clinical recurrence risk and progression in bladder cancer [3,4] .…”

Section: Introductionmentioning

confidence: 99%

Aurora-A/STK-15 Is Differentially Expressed in the Micropapillary Variant of Bladder Cancer

Compérat

Rouprêt²,

Conort³

et al. 2009

Urol Int

View full text Add to dashboard Cite

Introduction: Micropapillary carcinoma (MPC) of the bladder is a rare and aggressive histologic variant of urothelial carcinoma (UC). At the time of presentation, most MPC are muscle invasive with frequent vascular invasion (VI). Our series explores protein expression of markers known to be indicators of poor clinical outcome and progression, trying to explain aggressiveness of MPC. Patients and Methods: 18 patients with MPC were reviewed. We explored protein expression of p53, MIB-1, Aurora-A and survivin in MPC and compared their expression to conventional urothelial carcinoma (CUC) of the same grade and stage. Results: Patients, aged 46–85 years, underwent transurethral resection or cystoprostatectomy for UC. MPC was either pure (39%) or only partially present (61%). 55% of the patients died. VI was seen in 95%. MPC displayed overexpression of p53 and MIB-1, Aurora-A and survivin. No statistically significant difference could be made with CUC except for Aurora-A (p = 0.03). Conclusions: This is the first study to explore different markers of bad clinical outcome in MPC. We suggest that Aurora-A via mechanisms implied into early steps of mitosis might play a role in aggressive clinical behavior of MPC.

show abstract

Aurora-A/STK-15 is a predictive factor for recurrent behaviour in non-invasive bladder carcinoma: a study of 128 cases of non-invasive neoplasms

Cited by 40 publications

References 26 publications

Current Status of Prognostic Immunohistochemical Markers for Urothelial Bladder Cancer

Current Status of Prognostic Immunohistochemical Markers for Urothelial Bladder Cancer

Fluorescence diagnosis and flat lesions of urothelium: New challenges for pathologists and urologists (Review)

Aurora-A/STK-15 Is Differentially Expressed in the Micropapillary Variant of Bladder Cancer

Contact Info

Product

Resources

About